Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabazitaxel phase II trial in advanced adrenocortical carcinoma after prior chemotherapy
2017-001591-35Phase 2Completed
- Sponsor
- ASST Spedali Civili di Brescia
- Start
- Sep 2021
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cabazitaxel in adrenal cancer (ACC), sponsored by ASST Spedali Civili di Brescia. Primary endpoint: Non-progressing rate at 4 months. Started Sep 2021; status: completed.
02
Drugs
cabazitaxel
03
Conditions
adrenal cancer (ACC)
Beyond the preview
Go deeper on 2017-001591-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001591-35.